Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | HBB | P68871 | 2/20 | 0.76 |
| ▸ | CASP1 | P29466 | 1/20 | 0.76 |
| ▸ | CASP7 | P55210 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | GLA | P06280 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | STAT6 | P42226 | 1/20 | 0.73 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | GMNN | O75496 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29229512 | 0.94 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL8187235 | 0.93 | TOP1 (0.80) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL26911556 | 0.93 | TOP1 (0.82) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL1030270 | 0.93 | TOP1 (0.80) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL27748704 | 0.93 | TOP1 (0.80) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL26976681 | 0.93 | TOP1 (0.80) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL10633845 | 0.93 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL8506572 | 0.93 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL28291366 | 0.93 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL30516672 | 0.92 | TOP1 (0.78) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779138-B2 | Camptothecin derivatives as chemoradiosensitizing agents | Sutter West Bay Hospital (US) | 2014-07-15 | — | — | US | disclosed |
| US-8563537-B2 | Camptothecin derivatives as chemoradiosensitizing agents | Sutter West Bay Hospital (US) | 2013-10-22 | — | — | US | disclosed |
| EP-1951231-B1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | CALIFORNIA PACIFIC MED CENTER (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8168648-B2 | Camptothecin derivatives and uses thereof | TAIWAN LIPOSOME CO., LTD. (TW) | 2012-05-01 | — | — | US | disclosed |
| US-7875602-B2 | Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in cancer treatment in combination with radiotherapy; less toxic | SUTTER WEST BAY HOSPITALS (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100227877-A1 | NEW CAMPTOTHECIN DERIVATIVES AND USES THEREOF | TAIWAN LIPOSOME CO. LTD. (TW) | 2010-09-09 | — | — | US | disclosed |
| US-20080318873-A1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER | 2008-12-25 | — | — | US | disclosed |
| WO-2007048002-A2 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093432-A1 | Camptothecin derivatives as chemoradiosensitizing agents | CALIFORNIA PACIFIC MEDICAL CENTER | 2007-04-26 | — | — | US | disclosed |
| US-20070093432-A1 | Camptothecin derivatives as chemoradiosensitizing agents | CALIFORNIA PACIFIC MEDICAL CENTER | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227877-A1 | NEW CAMPTOTHECIN DERIVATIVES AND USES THEREOF | LDHA, LDHB, TOP2A | TOP1 6/4885MEN1 2681/4885KMT2A 2900/4885 |
| US-20070093432-A1 | Camptothecin derivatives as chemoradiosensitizing agents | ERCC2, CHEK1, ERCC4 | TOP1 16/4885MEN1 531/4885KMT2A 4282/4885 |
| US-20080318873-A1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | ERCC2, CHEK1, ERCC4 | TOP1 16/4885MEN1 531/4885KMT2A 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.